Phage therapy: Delivering on the promise

Therapeutic Delivery

Volumn 2, Issue 7, 2011, Pages 935-947

  Harper, D R ^a   Anderson, J ^b   Enright, M ^a  

^a AmpliPhi Biosciences   (United Kingdom)

^b AmpliPhi BioSciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PENICILLIN G; SULFAMIDOCHRYSOIDINE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOPHAGE; BACTERIOPHAGE THERAPY; BACTERIUM CULTURE; CONSERVATIVE TREATMENT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DRUG USE; DYSENTERY; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS; REVIEW; STAPHYLOCOCCUS;

EID: 79961206351     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.64     Document Type: Review

References (46)

1. Hankin EH. L'action bactericide des Eaux de la Jumna et du Gange sur le vibrion du cholera. Annales de L'Institute Pasteur 10, 511 (1896).
2. Twort FW. An investigation on the nature of ultramicroscopic viruses. Lancet 1241 (1915).
3. Duckworth DH. Who discovered bacteriophage? Bacteriol. Rev. 40, 793-802 (1976).
4. D'Herelle F. Sur un microbe invisible antagonistic des bacilles dysenteriqes. Comptes Rendus Acad. Sci. Paris 165, 373-375 (1917).
5. Bruynoghe R, Maisin J. Essais de therapeutique au moyen du bacteriophage du staphylocoque. Comptes Rendus des Séances et Mémoires de la Société de Biologie 85, 1120-1121 (1921).
6. d'Herelle F. Le bacteriophage - son role dans l' immunite. Masson et cie, Paris, France (1922).
7. Olsen RH, Thomas DD. Characteristics and purification of PRR1, an RNA phage specific for the broad host range Pseudomonas R1822 drug resistance plasmid. J. Virol. 12, 1560-1567 (1973).
8. Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-669 (2001).
9. Weber-Dabrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch. Immunol. Ther. Exp. 48, 547-551 (2000). (Pubitemid 32108401)
10. Matthews CK. Bacteriophage T4. In: The Encyclopedia of Life Sciences. John Wiley and Sons, Chichester, UK (2006).
11. Bertani G, Weigle JJ. Host controlled variation in bacterial viruses. J. Bacteriol. 65, 113-121 (1953).
12. Horvath P, Barrangou R. CRISPR/Cas, the immune system of bacteria and archaea. Science 327, 167-170 (2010).
13. Burnett FM, Lush D. Induced lysogenicity and mutation of bacteriophage within lysogenic bacteria. Australian J. Exp. Biol. Med. Sci. 14, 27-38 (1936).
14. Meader E, Mayer MJ, Gasson MJ, Steverding D, Carding SR, Narbad A. Bacteriophage treatment significantly reduces viable Clostridium difficile and prevents toxin production in an in vitro model system. Anaerobe 16, 549-554 (2010).
15. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128, 307-318 (1982). (Pubitemid 12159900)
16. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129, 2659-2675 (1983). (Pubitemid 13039611)
17. Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J. Gen. Microbiol. 133, 1111-1126 (1987). (Pubitemid 17086127)
18. Bruttin A, Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49, 2874-2878 (2005). (Pubitemid 40917605)
19. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. Bacteriophage therapy of venous leg ulcers in humans: results of a Phase I safety trial. J. Wound Care 18, 237-243 (2009).
20. Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-357 (2009).
21. Marza JA, Soothill JS, Boydell P, Collyns TA. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32, 644-646 (2006).
22. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42, 1915-1922 (2004). (Pubitemid 38637802)
23. Pearl S, Gabay C, Kishony R, Oppenheim A, Balaban NQ. Nongenetic individuality in the host-phage interaction. PLoS Biol. 6, e120 (2008).
24. Merabishvili M, Pirnay JP, Verbeken G et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4, e4944 (2009).
25. Carmody LA, Gill JJ, Summer EJ et al. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201, 264-271 (2010).
26. Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of bacteriophages KS4-M and FKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 110, 106-117 (2011).
27. Soothill JS. Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 37, 258-261 (1992).
28. Wang J, Hu B, Xu M et al. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 17, 309-317 (2006).
29. Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51, 446-452 (2007). (Pubitemid 46185259)
30. Vinodkumar CS, Kalsurmath S, Neelagund YF. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J. Pathol. Microbiol. 51, 360-366 (2008).
31. Dubos RJ, Straus, JH, Pierce C. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with Shigella dysenteriae. J. Exp. Med. 78, 161-168 (1943).
32. Schluesenera HJ, Xianglin T. Selection of recombinant phages binding to pathological endothelial and tumor cells of rat glioblastoma by in vivo display. J. Neurol. Sci. 224, 77-82 (2004). (Pubitemid 39278265)
33. Merril CR, Biswas B, Carlton R et al. Long-circulating bacteriophage as antibacterial agents. Proc. Natl Acad. Sci. USA 93, 3188-3192 (1996). (Pubitemid 26125592)
34. Kim K-P, Cha J-D, Jang EH et al. PEGylation of bacteriophages increases blood circulation time and reduces T-helper type 1 immune response. Microb. Biotechnol. 1, 247-257 (2008).
35. Letarov A, Kulikov E. The bacteriophages in human- and animal body-associated microbial communities. J. Appl. Microbiol. 107, 1-13 (2009).
36. Puapermpoonsiri U, Spencer J, van der Walle CF. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur. J. Pharm. Biopharm. 72, 26-33 (2009).
37. Fiers W, Contreras R, Duerinck F et al. Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. Nature 260, 500-507 (1976).
38. Sanger F, Air GM, Barrell BG et al. Nucleotide sequence of bacteriophage phi X174 DNA. Nature 265, 687-695 (1977). (Pubitemid 8039446)
39. Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J. Gen. Virol. 67, 1759-1816 (1986). (Pubitemid 16017266)
40. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. Genbank. Nucleic Acids Res. 36, D25-D30 (2008). (Pubitemid 351149691)
41. Leplae R, Hebrant A, Wodak SJ, Toussaint A. ACLAME: a classification of mobile genetic elements. Nucleic Acids Res. 32, D45-D49 (2004). (Pubitemid 38081601)
42. Overbeek R, Begley T, Butler RM et al. The subsystems approach to genome annotation and its use in the project to annotate 1000 genomes. Nucleic Acids Res. 33, 5691-5702 (2005). (Pubitemid 41548835)
43. Jensen MA, Faruque SM, Mekalanos JJ, Levin BR. Modeling the role of bacteriophage in the control of cholera outbreaks. Proc. Natl Acad. Sci. USA 103, 4652-4657 (2006).
44. Faruque SM, Naser IB, Islam MJ et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. Proc. Natl Acad. Sci. USA 102, 1702-1707 (2005). (Pubitemid 40209231)
45. Faruque SM, Islam MJ, Ahmad QS et al. Self-limiting nature of seasonal cholera epidemics: Role of host-mediated amplification of phage. Proc. Natl Acad. Sci. USA 102, 6119-6124 (2005). (Pubitemid 40594265)
46. Harper DR. Viruses: biology, applications and control. Garland Science, Abingdon, UK (2011).